Clinical experience with epothilones in patients with breast cancer

Clinical Breast Cancer

Volumn 8, Issue SUPPL. 2, 2008, Pages

  Buzdar, Aman U ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Antimicrotubule agents; Ixabepilone; P glycoprotein; Triple negative breast cancer

Indexed keywords

21 AMINOEPOTHILONE B; ANTHRACYCLINE; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; ESTROGEN RECEPTOR; IXABEPILONE; PACLITAXEL; PROGESTERONE RECEPTOR; SAGOPILONE; TAXANE DERIVATIVE; TRASTUZUMAB; TUBULIN MODULATOR;

ADJUVANT CHEMOTHERAPY; ADRENAL CANCER; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; ATAXIA; BLADDER CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; COLORECTAL CANCER; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; ENDOMETRIUM CANCER; FATIGUE; FEBRILE NEUTROPENIA; GAIT; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; HYPONATREMIA; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PERCEPTION; PERIPHERAL NEUROPATHY; PLASMA CONCENTRATION-TIME CURVE; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH CANCER; STOMATITIS; TESTIS CANCER; VOMITING; BREAST TUMOR; FEMALE; PATHOLOGY; TREATMENT OUTCOME;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; EPOTHILONES; FEMALE; HUMANS; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 52449115718     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.s.003     Document Type: Article

References (64)

1. Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer 2004; 100:44-52.
2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717.
3. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21:976-83.
4. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for nodepositive breast cancer. N Engl J Med 2005; 352:2302-13.
5. O'Driscoll L, Clynes M. Biomarkers and multiple drug resistance in breast cancer. Curr Cancer Drug Targets 2006; 6:365-84.
6. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005; 205:275-92.
7. Porkka K, Blomqvist C, Rissanen P, et al. Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. J Clin Oncol 1994; 12:1639-47.
8. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17:485-93.
9. Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracyclineand taxane-pretreated metastatic breast cancer. Eur J Cancer 2004; 40:536-42.
10. Hillan KJ, Koeppen HK, Tobin P, et al. The role of VEGF expression in response to bevacizumab plus capecitabine in metastatic breast cancer (MBC). Proc Am Soc Oncol 2003; 22:191. (Abstract 766).
11. Pierga JY, Fumoleau P, Brewer Y, et al. Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program. Breast Cancer Res Treat 2004; 88:117-29.
12. Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al. Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with meta-static breast cancer relapsing after treatment with a taxane-contain-ing therapy. Ann Oncol 2003; 14:1227-33.
13. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55:2325-33.
14. Gupta ML, Jr, Bode CJ, Georg GI, et al. Understanding tubulin-Taxol interactions: mutations that impart Taxol binding to yeast tubulin. Proc Natl Acad Sci U S A 2003; 100:6394-7.
15. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001; 7:1429-37.
16. Jordan MA, Miller H P, Ni L, et al. The Pat-21 breast cancer model derived from a patient with primary Taxol® resistance recapitulates the phenotype of its origin, has altered beta-tubulin expression and is sensitive to ixabepi-lone Proc Am Assoc Cancer Res 2006; 47:Abstract LB-280.
17. Wartmann M, Altmann KH. The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents 2002; 2:123-48.
18. Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 2003; 10:43-73.
19. Aghajanian C, Burris HA, 3rd, Jones S, et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 2007; 25:1082-8.
20. Gadgeel SM, Wozniak A, Boinpally RR, et al. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res 2005; 11:6233-9.
21. Mani S, McDaid H, Hamilton A, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004; 10:1289-98.
22. Bunnell C, Klimovsky J, Thomas E. Final efficacy results of a phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline. J Clin Oncol 2006; 24(18 suppl):568s (Abstract 10511).
23. Lee H, Xu L, Wu S, et al. Predictive biomarker discovery and validation for the targeted chemotherapeutic ixabepilone. J Clin Oncol 2006; 24(18 suppl):123s (Abstract 3011).
24. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007; 25:3407-14.
25. Roche H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepi- lone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007; 25:3415-20.
26. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007; 25:3399-406.
27. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and tax-ane treatment. J Clin Oncol 2007; 25:5210-7.
28. Bonneterre J, Roche H, Monnier A, et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 2002; 87:1210-5.
29. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23:5542-51.
30. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999; 17:1413-24.
31. Sjostrom J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35:1194-201.
32. Valero V, Jones SE, Von Hoff DD, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998; 16:3362-8.
33. Lee FY, Camuso S, Castenada S, et al. Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts. J Clin Oncol 2006; 24(18 suppl):597s (Abstract 12017).
34. Lee FY, Castaneda S, Inigo I, et al. Ixabepilone (BMS-247550) plus trastuzumab combination chemotherapy induces synergistic antitumor efficacy in HER2 dependent breast cancers and is accompanied by modulation of molecular response markers. J Clin Oncol 2005; 23(16 suppl):19s (Abstract 561).
35. Lee FY, Castenada S, Hawkin D, et al. Bevacizumab/Ixabepilone (BMS-247550) combination produces synergistic antitumor efficacy in multiple tumor models in vivo and is superior to bevacizumab/paclitaxel combination. Presented at: the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications; November 14-18, 2005; Philadelphia, PA. Abstract 3243.
36. Vahdat L, Bunnell C, Schwartzberg L, et al. Ixabepilone is effective in combination with capecitabine in ER, PR, HER-2 negative (triple negative) patients (pts) resistant to taxanes and anthracyclines: final results from a breast cancer exploratory program. Ann Oncol 2006; 17(suppl 9):Abstract 159P.
37. Kaufmann P, Dauphine CE, Vargas M P, et al. Success of neoadjuvant chemotherapy in conversion of mastectomy to breast conservation surgery. Am Surg 2006; 72:935-8.
38. Chang J, Hilsenbeck S, Yee D, et al. Gene expression profiles as predictors of response to neoadjuvant taxotere and adriamycin/cytoxan: a prospective randomized multicenter trial in breast cancer. Breast Cancer Res and Treat 2005; 94(suppl 1):S31 (Abstract 304).
39. Gradishar WJ, Wedam SB, Jahanzeb M, et al. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol 2005; 16:1297-304.
40. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21:4165-74.
41. Gianni L, Baselga J, Eiermann W, et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005; 11:8715-21.
42. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005; 23:5983-92.
43. Baselga J, Gianni L, Llombart A, et al. Predicting response to ixabepi-lone: genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (BC). Breast Cancer Res Treat 2005; 94(suppl 1):(Abstract 305).
44. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13:2329-34.
45. Roche H, Perez E, Llombart Cussac A, et al. Ixabepilone, an epothilone B analog, is effective in ER, PR, HER-2 negative (triple negative) patients (pts): data from neoadjuvant and metastatic breast cancer (MBC) trials. Ann Oncol 2006; 17(suppl 9):(Abstract 256P).
46. ClinicalTrials.gov [Web site]. Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer. Available at: http://clinicaltrials.gov/ct2/show/ NCT00082433. Accessed: January 4, 2008.
47. Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 2007; 12:271-80.
48. Goodin S, Kane M P, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004; 22:2015-25.
49. Fumoleau P, Coudert B, Isambert N, et al. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol 2007; 18 (suppl 5):v9-15.
50. Klar U, Buchmann B, Schwede W, et al. ZK-EPO, a novel synthetic epothilone B analog, significantly inhibits tumor growth in both nonresistant and resistant breast cancer models. Breast Cancer Res and Treat 2005; 94(suppl 1):S64 (Abstract 1072).
51. Schmid P, Kiewe D, Kuehnhardt A, et al. A Phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors. J Clin Oncol 2005; 23 (16 suppl):147s (Abstract 2051).
52. ClinicalTrials.gov [Web site]. Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer. Available at: http://www.clinicaltri-als.gov/ct2/ show/NCT00313248. Accessed: November 28, 2007.
53. ClinicalTrials.gov [Web site]. ZK219477 in Patients With Breast Cancer and Brain Metastases. Available at: http://www.clinicaltrials. gov/ct2/show/NCT00496379. Accessed: November 28, 2007.
54. Mekhail T, Chung C, Holden S, et al. Phase I trial of novel epothilone B analog BMS-310705 IV q 21 days Proc Am Soc Clin Oncol 2003; 22:129 (Abstract 515).
55. Sessa C, Perotti A, Malossi A, et al. Phase I and pharmacokinetic (PK) study of the novel epothilone BMS-310705 in patients (pts) with advanced solid cancer. Proc Am Soc Clin Oncol 2003; 22:130 (Abstract 519).
56. Buzdar A, Silverman P, Kaufman PA, et al. A phase II study of KOS-862 (epothilone D) in anthracycline and taxane pretreated meta- static breast cancer: updated results. Breast Cancer Res Treat 2005; 94(suppl 1):(Abstract 1087).
57. Cortes J, Climent MA, Gomez P, et al. A phase I trial of weekly combination KOS-862 (epothilone D) and trastuzumab in HER-2 overexpressing malignancies. J Clin Oncol 2006; 24(suppl):86s (Abstract 2028).
58. ClinicalTrials.gov [Web site]. A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer. Available at: http://clinical-trials.gov/ct2/show/ NCT00490646. Accessed: January 4, 2008.
59. ClinicalTrials.gov [Web site]. A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00370552. Accessed: January 4, 2008.
60. Calvert PM, O'Neill V, Twelves C, et al. A Phase I Clinical and Pharmacokinetic Study of EPO906 (Epothilone B), Given Every Three Weeks, in Patients with Advanced Solid Tumors. Proc Am Soc Clin Oncol 2001; 20:(Abstract 429).
61. Rubin EH, Rothermel J, Tesfaye F, et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 2005; 23:9120-9.
62. Holen KD, Syed S, Hannah AL, et al. Phase I study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors. J Clin Oncol 2004; 22(14 suppl):133 (Abstract 2024).
63. Piro LD, Rosen LS, Parson M, et al. KOS-862 (epothilone D): A comparison of two schedules in patients with advanced malignancies. Proc Am Soc Clin Oncol 2003; 22:135 (Abstract 539).
64. Spriggs DR, Dupont J, Pezzulli S, et al. KOS-862 (Epothilone D): Phase 1 dose escalating and pharmacokinetic (PK) study in patients with advanced malignancies Proc Am Soc Clin Oncol 2003; 22:223 (Abstract 894).